Use of Lactobacillus helveticus BGRA43 for Manufacturing Fermented Milk Products by Ivana Strahinic et al.
ISSN 1330-9862 original scientific paper
(FTB-3078)
Use of Lactobacillus helveticus BGRA43 for Manufacturing
Fermented Milk Products
Ivana Strahinic1*, Jovanka Lukic1, Amarela Terzic-Vidojevic1, Jelena Lozo1,2,
Milan Kojic1 and Ljubisa Topisirovic1
1Institute of Molecular Genetics and Genetic Engineering, University of Belgrade,
Vojvode Stepe 444/a, P.O. Box 23, RS-11010 Belgrade, Serbia
2Faculty of Biology, University of Belgrade, Studentski trg 16, RS-11000 Belgrade, Serbia
Received: April 25, 2012
Accepted: December 13, 2012
Summary
Lactobacillus helveticus BGRA43 isolated from human intestines shows antimicrobial ac-
tivity against foodborne pathogens and during fermentation in milk releases peptides with
demonstrated anti-inflammatory properties. In this study, it was found that strain BGRA43
exhibits antimicrobial activity against human pathogens Yersinia enterocolitica, Shigella son-
nei, S. flexneri and Streptococcus pneumoniae. Strain BGRA43 was able to survive in simu-
lated gastric juice containing milk and retained cell number stability during the incubation
in simulated intestinal conditions. In addition, LC/MS/MS analysis showed the ability of
BGRA43 to hydrolyze b-lactoglobulin. Abundant growth of strain BGRA43 occurred in the
presence of prebiotics inulin or concentrated oat bran b-glucan (Nutrim®), even when used
as the sole carbon source. Similarly, strain BGRA43 grew satisfactorily in pure cow's or
goat's milk as well as in the milk containing inulin or Nutrim®. Using the probiotic strain
BGRA43 as a single starter strain, fermented milk products obtained from cow's or goat's
milk with or without inulin or Nutrim® contained about 107 CFU/mL. The products were
homogeneous and viscous and the best sensory scores were observed for fermented milk
beverage made from reconstituted skimmed milk, whole cow's milk and whole goat's milk
supplemented with 1 % inulin.
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Introduction
Gut microbiota has an important role in human
health and diseases. Among them, some lactobacilli and
bifidobacteria have been reported to exert health bene-
fits ranging from interaction with harmful bacteria in the
gut to the restoration of gut epithelial and immune ho-
meostasis (1). The knowledge that different lactobacilli
could be a source of new probiotics has been expanded
(2). Moreover, fermented dairy products containing
probiotics have been used to establish microbial balance
in the intestines, facilitate dietary digestion or prevent
pathogen colonisation (3,4). Furthermore, it was shown
that milk, whey proteins and mucin could protect bacte-
rial cells during transit through the gastrointestinal (GI)
tract (5). Milk contains two main protein classes, which
are the caseins (aS1-, aS2-, k- and b-casein) and whey
proteins (b-lactoglobulin, a-lactalbumin, bovine serum
albumin and lactoferrin). Large population studies of in-
fants allergic to cow's milk have shown that the major
allergens are b-lactoglobulin (BLG) and aS1-casein (6).
In the last years, the use of probiotics such as lactic acid
bacteria (LAB) has been proposed as an alternative for
the management of allergenic diseases. Proteolysis of
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BLG by LAB could increase its digestibility by releasing
smaller peptides, which are known to be less immuno-
reactive and could be better absorbed in the intestinal
tract (7).
The basis for selection of probiotic microorganisms
includes their human origin, biosafety aspects, acid and
bile tolerance, colonisation of the intestine, antimicrobial
activity, immunomodulation, and/or prevention of patho-
gen growth (2). In addition, probiotic bacteria should
have desirable technological properties such as superior
growth rate in milk or other food bases and stability
during processing and storage, which should result in a
final product with satisfactory sensory properties and a
significant impact on nutritional quality (8). One of the
main criteria for selection of a probiotic strain is its sur-
vival in the gastrointestinal environment. Therefore, sim-
ple in vitro simulation tests for screening have been de-
signed (9). Other characteristics required for a probiotic
strain include the ability to inhibit the growth of various
pathogens by production of lactic and acetic acids, hy-
drogen peroxide, bacteriocins, bacteriocin-like substances
and biosurfactants (10). These antagonistic effects in fer-
mented products could be very useful against foodborne
pathogens, and also against human pathogenic bacteria,
particularly enteropathogens like Salmonella, Listeria and
Campylobacter (11).
In order to stimulate selectively the viability of a par-
ticular probiotic strain in fermented products or the GI
tract, appropriate prebiotics have been used (12). Prebio-
tic inulin is a low-calorie carbohydrate found in certain
roots and tubers. It affects different functions of the or-
ganism and colonic microflora, immune function, avail-
ability of minerals, lipid metabolism and normal func-
tioning of the digestive tract (13,14). Experiments also
showed that the ingestion of inulin improved calcium
absorption and enhanced bone mineralization (15). Nu-
trim® is a new-generation oat bran that contains carbo-
hydrates (hydrocolloids) formulated to reduce plasma
cholesterol levels by promoting the increased excretion
of bile acids (16). In addition, soluble b-glucans provide
maintenance of optimal blood sugar level (17). Prebio-
tic-containing diets have been shown to change popula-
tions of Bifidobacterium and Lactobacillus in the GI tract
increasing their number by 10-fold. On the other hand,
prebiotics also specifically decrease the population of other
anaerobes, for instance, sulphite-reducing clostridia (18).
Research regarding probiotic properties of Lactobacil-
lus helveticus strains included studies on immunomodu-
lation in animal models (19), as well as on their antago-
nism to pathogens (3). It was also demonstrated that
peptides released during fermentation of reconstituted
skimmed milk by L. helveticus had strong ACE-inhibi-
tory activity (20,21). It had been shown previously that
human intestinal isolate L. helveticus BGRA43 (formerly
Lactobacillus acidophilus BGRA43) exhibited an inhibitory
activity against various strains of Lactococcus, Lactobacil-
lus, Staphylococcus, Bacillus and Pseudomonas species, as
well as the foodborne pathogen Clostridium sporogenes (22).
Additionally, the whole BGRA43 cells were able to hy-
drolyze aS1-, b- and k-caseins completely (23). Moreover,
protein fractions released during the fermentation of milk
with BGRA43 strain showed inhibitory effect on human
monocyte RB, as well as anti-inflammatory effect on
THP-1 cells (24).
The aim of our study is further examination of pro-
biotic features of the BGRA43 strain including antimi-
crobial activity against several human pathogenic bacte-
ria, resistance to simulated gastrointestinal conditions
(pH=2, bile salts, presence of pepsin and pancreatin) and
its ability to hydrolyze BLG. The final goal of this study
is the implementation of potential probiotic strain as start-
er culture in dairy production. Consequently, the fermen-
tation abilities of BGRA43 during growth in skimmed
and whole cow's milk and whole goat's milk are exam-
ined. Moreover, the fermentation ability of BGRA43 strain
in all three milk samples containing prebiotic inulin or
Nutrim® is tested. The survival of bacteria in the result-
ing fermented milk product after 7 days of storage at 4
°C is also reported.
Materials and Methods
Bacterial strains, media and culture conditions
Strain L. helveticus BGRA43 isolated from faecal sam-
ples of healthy men was cultured in liquid MRS broth
(Oxoid, Basingstoke, UK) or in a medium prepared from
reconstituted skimmed milk (RSM) powder 10 % (by mass
per volume), obtained from Subotica dairy plant, Serbia,
and sterilized by autoclaving at 110 °C for 20 min. The
isolates were stored at –80 °C in MRS broth (Oxoid) sup-
plemented with 15 % (by volume) glycerol. When the
active culture was needed, the frozen culture was inocu-
lated in MRS broth at 37 °C during 16 h.
In order to determine the growth rate in the pres-
ence of different sugars, BGRA43 strain was grown in a
chemically defined medium (CDM) for lactobacilli con-
taining in g/L: sodium acetate 6, ammonium citrate 1,
K2HPO4 3, KH2PO4 3, MgSO4·7H2O 0.5, MnSO4·H2O 0.032,
FeSO4·7H2O 0.02, casitone 20 g/L; in mg/L: p-aminoben-
zoic acid 0.2, folic acid 0.1, nicotinic acid 1, pantothenic
acid 1, pyridoxal 2, riboflavin 1, biotin 1; and in mL/L:
polyethylene sorbitan monooleate 1. Either glucose, lac-
tose (Sigma Chemie GmbH, Deisenhofen, Germany),
inulin (FutureCeuticals, Santa Rosa, CA, USA) or the
low-glycemic carbohydrate product, Nutrim® (Future-
Ceuticals) were added to the CDM at 1 % (by mass per
volume) final fraction. All components were filtered or
autoclaved (121 °C for 15 min) prior to use.
In this study, in addition to RSM, commercial ultra-
-heat treated (UHT) whole cow's milk (WCM) obtained
from a local supermarket and whole goat's milk (WGM)
obtained from a local farm were used. Inulin (1 %, by
mass per volume) or Nutrim® (1 %, by mass per vol-
ume) were added to the RSM, WCM and WGM at the
same time as BGRA43 inoculation was performed.
The human pathogenic strains used as indicators in
the antimicrobial activity assay were cultivated in the fol-
lowing media: Baird-Parker medium (Staphylococcus au-
reus), blood agar with tryptone (15 g/L), bovine heart
extract (3 g/L), and NaCl (5 g/L) with the addition of 7
% (by volume) sheep blood (Streptococcus pneumoniae),
Columbia agar with the addition of 5 % (by volume) of
horse blood (Bacillus sp.), Mueller-Hinton medium (Shi-
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gella and Candida species, Micrococcus flavus and Yersinia
enterocolitica), all obtained from Torlak (Institute of Virol-
ogy, Vaccines and Sera, Belgrade, Serbia). When a solid
medium was required, agar (2 %, by mass per volume;
Torlak) was added to each medium. The plates were in-
cubated overnight at 30 or 37 °C depending on the strain
involved.
Assay of antimicrobial activity
For the detection of antimicrobial activity, BGRA43
strain was inoculated in MRS broth and incubated at 37
°C for 16 h. The antimicrobial activity was tested by the
agar well diffusion assay (22) against the following indi-
cator strains: Streptococcus pneumoniae, Yersinia enterocoli-
tica, Shigella spp., Bacillus spp., Staphylococcus aureus, Mi-
crococcus spp. and Candida spp. The results are expressed
as the mean diameter of triplicate independent experi-
ments for each sample.
The cumulative effect of simulated gastrointestinal
juices on L. helveticus BGRA43 survival
The viability of BGRA43 strain during simulated gas-
trointestinal digestion (gastrointestinal passage) was test-
ed as previously described (25) with minor modifications.
Artificial gastric juice was formulated using (in g/L): NaCl
7.31, KCl 0.52, NaHCO3 3.78, adjusted to pH=2 using
concentrated HCl. After sterilisation, filtered pepsin (3
g/L) was added. Two artificial intestinal juices (A and B)
were composed to simulate conditions in the duodenum
and ileum during intestinal transit. Intestinal juice A was
prepared by suspending 0.6 % (by mass per volume) of
bile salts in distilled water, adjusted to pH=8 using 10 M
NaOH and autoclaved. Intestinal juice B consisted of 0.3
% (by mass per volume) of bile salts in distilled water,
and, after autoclaving, pancreatin (1 g/L) was added with-
out filtration. Pepsin (from porcine stomach mucosa) and
pancreatin (from porcine pancreas) were purchased from
Sigma. Bile salts were obtained from Torlak.
A fresh overnight culture of BGRA43 (16 h) prepared
in MRS was split in two tubes each containing 10 mL.
Cells were collected by centrifugation at 3200´g for 15
min and resuspended in 2 mL of saline (tube 1) or 2 mL
of 10 % RSM (tube 2). Subsequently, gastric juice (8 mL)
was added to each tube. The addition of milk resulted in
the increase of pH of the suspension from pH=2 to 5.63.
The obtained mixtures were incubated for 90 min at 37
°C with agitation (~58 rpm) to simulate peristalsis. After-
wards, the two bacterial suspensions were centrifuged at
3200´g for 15 min, the pellets resuspended in 10 mL of
simulated intestinal juice A and incubated for 10 min at
37 °C under anaerobic conditions. After that, the cells
were pelleted at 3200´g for 15 min and finally resus-
pended in intestinal juice B (10 mL) and incubated an-
aerobically for 120 min at 37 °C. Aliquots (100 mL) from
each tube were taken for enumeration of viable cells at
0, 30, 60, 90, 100, 160 and 220 min.
Hydrolysis of b-lactoglobulin
Proteolytic activity of the BGRA43 strain was ana-
lyzed as described previously (23) with slight modifica-
tions. Briefly, after growth on milk citrate agar (MCA)
plates, cells were collected, resuspended in 100 mM so-
dium phosphate buffer (pH=6.8) and the absorption (UV-
-VIS spectrophotometer, Cary®, Varian, NC, USA) was
measured at 600 nm. As substrate, 3 mg/L of b-lacto-
globulin (Lactalis, Rétiers, France) dissolved in the same
buffer and heated at 80 °C for 30 min was used. The cell
suspension was diluted in 100 mM sodium phosphate
buffer (pH=6.8) with the substrate in 1:1 ratio to obtain a
final A600 nm=20 and incubated for 0, 9 and 24 h at 37 °C.
The samples were then centrifuged (at 10 000´g, 10 min,
4 °C) and the supernatants with the products of hydro-
lysis were analyzed by reversed phase high performance
liquid chromatography (RP-HPLC). The samples were
made in three independent experiments before further
analysis by RP-HPLC.
Liquid chromatography-tandem mass spectrometry
analyses
The peptides released from BLG hydrolysis by L.
helveticus BGRA43 were analyzed by mass spectrometry
using an LCQ Advantage ion trap mass spectrometer
(Thermo Fisher Scientific, San Jose, CA, USA) as de-
scribed previously (26) with minor modifications. For
peptide reduction, samples were dissolved in a reduc-
tion buffer (50 mM Tris, 10 mM dithiotreitol, and 0.6 M
guanidinium chloride, pH=8.5), and incubated for 1 h at
45 °C. Alkylation of free sulphydryl group was per-
formed by adding 1.0 M iodoacetamide to a final con-
centration of 5 mM. After incubation for 30 min at room
temperature in the dark, the reaction was stopped by
adding trifluoroacetic acid (TFA) to a final volume frac-
tion of 0.1 %. Samples were desalted again by solid-
-phase extraction (SPE) on a Sep-Pak C18 cartridge (Wa-
ters, Milford, MA, USA). After rinsing the cartridge with
0.1 % TFA (by volume) solution, 5 mL of the sample
were loaded into the cartridge, and the peptides were
eluted using a water/acetonitrile/TFA (20:80:0.09, by
volume) solution.
Raw data collected during the LC-MS/MS run were
processed by Bioworks v. 3.1 browser software (Thermo
Fisher) and converted into MASCOT generic format (mgf)
files to be further searched against databanks using MAS-
COT server v. 2.2 (Matrix Science, London, UK).
Growth of L. helveticus BGRA43 strain in different
milk types
The ability of BGRA43 to coagulate milk was studied
in nine prepared milk combinations (RSM, RSM+1 % inu-
lin, RSM+1 % Nutrim®, WCM, WCM+1 % inulin, WCM+1
% Nutrim®, WGM, WGM+1 % inulin and WGM+1 %
Nutrim®) under laboratory conditions. For this purpose,
2 L of RSM were inoculated with 60 mL of fresh over-
night culture of BGRA43 strain previously grown in MRS
broth and incubated for 16 h at 37 °C. After incubation,
30 mL (3 %) of this culture were used for inoculation of
nine different milk combinations (1 L each). The fermen-
tation was carried out at 42 °C. After 4 h, the fermenta-
tion was stopped, since milk was coagulated. The pH
value of milk and fermented milk products was mea-
sured during 0, 2, 3, 3.5 and 4 h of fermentation with a
pH meter (model HI 9311, HANNA Instruments, Lisbon,
Portugal) at room temperature. At the same time, titrat-
able acidity of milk and fermented milk products was
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determined according to the method proposed elsewhere
(27) and expressed in Soxhlet-Henkel degrees (°SH). In
addition, CFU, pH and °SH values were also measured
after 1 and 7 days of storage at 4 °C.
Apparent viscosity measurement
Viscometer VISCO BASIC Plus (Fungilab S.A., Bar-
celona, Spain) was used to measure the viscosity of fer-
mented milk products after 1 and 7 days of storage at 4
°C. Spindle no. 3 was used. All measurements were per-
formed at (18±1) °C. Viscosity readings were done at a
constant speed. The spindle speed was initially 100 rpm
for 30 s, then it was adjusted to 20 rpm and the readings
were carried out every 30 s (a total of six readings). The
change of viscosity of fermented milk products at 20 rpm
was investigated by the method described by Labropou-
los et al. (28). According to this method, viscosity values
were recorded during an estimated time following the
moment of the first value shown on the display, which
was taken as time zero. Viscosity values were recorded
every 30 s, during 3 min. This research was conducted
in two repetitions, and for each repetition a new sample
was used.
Sensory evaluation
The sensory evaluation of nine manufactured fer-
mented milk products was done by a panel of 5 sensory
analysts. The products were equilibrated at room tem-
perature when the sensory session started. Acceptable
sensory characteristics (colour, taste, odour and consis-
tency) were evaluated on a 5-point scale (1 – the worst; 5
– the best). The data were collected from each analyst in-
dependently. The reference sensory properties are as fol-
lows: for colour – typical, characteristic, intensive white;
for taste – sour, characteristic, yoghurt-like; for odour –
characteristic and intensive; and for consistency – uni-
form and compact, creamy, not lumpy and without sy-
neresis.
Statistical data analyses
Presented results are the mean values (x) calculated
based on three independent measurement results (x±s),




The inhibitory activity of fresh overnight culture of
BGRA43 strain, cell-free filtrate and neutralized cell-free
filtrate were determined by an agar well diffusion assay.
The results showed that the antimicrobial activity could
be detected only in case when wells were loaded with
fresh overnight culture of BGRA43. The strongest effect
was expressed against enteropathogenic strains of Yersi-
nia enterocolitica, Shigella sonnei and Shigella flexneri (Lon-
don 9950), as well as Streptococcus pneumoniae. Fresh
overnight culture of BGRA43 did not inhibit the growth
of Micrococcus, Salmonella and Candida species tested in
this study (Table 1). Moreover, cell-free filtrate and neu-
tralized cell-free filtrate were fully ineffective in all cases.
Effects of simulated gastrointestinal tract conditions
on the viability of L. helveticus BGRA43 cells
The ability of BGRA43 cells to survive in simulated
GI tract conditions was monitored. The starting over-
night culture at zero time had (3.12±0.32)·108 CFU/mL.
After incubation for 90 min in pure gastric juice, the
CFU decreased by approx. 5 log units. Successive 10-min-
ute incubation periods in intestinal juice A containing a
high bile salt fraction (0.6 %) led to an additional de-
crease in the number of living cells and CFU were unde-
tectable (<1 log CFU/mL). The small number of CFU re-
mained after further incubation of cells in intestinal juice
B (Fig. 1).
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Table 1. Antimicrobial activity of Lactobacillus helveticus BGRA43




Streptococcus pneumoniae ATCC 496 +++
Yersinia enterocolitica O3 (clinical isolate) Torlak collection +++
Shigella sonnei (Hamburg IO5) Torlak collection +++
Shigella flexneri (London 9950) Torlak collection +++
Shigella flexneri (clinical isolate) Torlak collection +
Shigella dysenteriae (serotype 5 and 7) Torlak collection +
Bacillus subtilis ATCC 8 +
Bacillus cereus ATCC 11778 +
Staphylococcus sp. Metr (clinical isolate) Torlak collection +
Micrococcus flavus ATCC 10240 –
Salmonella sp. (clinical isolate) Torlak collection –
Candida sp. (clinical isolate) Torlak collection –
diameter of inhibition zone: + up to 2 mm, +++ over 4 mm, –
no inhibition zone
Fig. 1. Survival of Lactobacillus helveticus BGRA43 in simulated
GI tract conditions in the presence or absence of milk. Pure gas-
tric juice (pH=2.0) contained pepsin 3 g/L. Intestinal juice A
(pH=8.0) contained 0.6 % bile salts, while intestinal juice B (pH=
8.0) contained 0.3 % bile salts and pancreatin 1 g/L
 – number of cells at the beginning of the experiment, –– –
BGRA43 in pure gastric juice, –– – BGRA43 in intestinal juice
A after incubation in pure gastric juice, ---- – BGRA43 in intes-
tinal juice B after incubation in intestinal juice A, –– – BGRA43
in gastric juice containing milk, –– – BGRA43 in intestinal juice
A after incubation in gastric juice containing milk, ---- – BGRA43
in intestinal juice B after incubation in intestinal juice A
The influence of milk as a protector on the survival
of BGRA43 under the simulated GI conditions was also
determined. Incubation of BGRA43 in gastric juice con-
taining milk enabled better survival. Interestingly, CFU/
mL increased from (3.12±0.32)·108 to (1.2±0.12)·109 dur-
ing the first 30 min of incubation in gastric juice with
milk but then remained more or less the same over the
next 60 min, i.e. up to 90 min of incubation in total.
Transfer of cells into intestinal juice A, and a further
10-minute incubation resulted in a decline of CFU by 3
log units. After 2 h of incubation in intestinal juice B,
there was a negligible decrease of living cell numbers
that remained over 106 CFU/mL until the end of the ex-
periment (Fig. 1).
LC/MS/MS analyses of peptides released from BLG
hydrolysis by L. heleveticus BGRA43
SDS-PAGE and RP-HPLC analyses showed that the
hydrolysis of BLG by BGRA43 observed after 9 and 24 h
of incubation was without any significant differences (data
not shown). Samples obtained after 24 h of incubation
were used to obtain the highest quantity of peptides.
The obtained peptides were identified by mass spectro-
metry analysis, which was performed on a sample hy-
drolyzed by BGRA43 without any modifications to avoid
losing small-size peptides. The same hydrolysate was
additionally desalted after the reduction and carboxy-
methylation to identified peptides linked by disulphide
bridges. Recovery of the sequences after mass spectro-
metry analysis was not complete. Since our results are
not quantitative, it is possible that peptides smaller than
400 Da present in very small amounts were not detected.
The size of the peptides identified after hydrolysis of BLG
with BGRA43 varied from 5 to 17 amino acids (559.95 to
1942.64 Da; Table 2 and Fig. 2). The 50 % of peptides
have hydrophobic amino acid on their C-terminal end
and another 30 % have basic amino acid lysine.
Technological properties of L. helveticus BGRA43
To compare the ability of BGRA43 to grow in the
presence of lactose, glucose and the prebiotics inulin or
Nutrim®, CDM containing one of the carbohydrate sour-
ces was inoculated with BGRA43 and incubated for 16
h. The results showed that total count of BGRA43 cells
was fairly similar, ranging between 2.5·107 and 7.5·107
CFU/mL depending on the carbon source.
Furthermore, the ability of BGRA43 to grow and co-
agulate milk as a monoculture was followed in RSM,
WCM and WGM with or without added inulin or Nu-
trim®. The total number of viable BGRA43 cells used as
a starter was 8.4·109 CFU/mL. The initial number of via-
ble cells counted in each nine milk combinations was be-
tween 1.9·106 and 5.6·106 CFU/mL. The number of viable
cells after 4 h of incubation and cooling was about 108
CFU/mL, except in the case when cells were grown in
RSM supplemented with inulin or Nutrim®. Despite the
fact that total cell number was one log unit lower, it did
not prevent the coagulation. Cell counts of BGRA43 were
not lower than 107 CFU/mL in any case, even after 7
days of storage at 4 °C (Table 3).
Data for pH value measurements obtained after 4 h
of fermentation were similar for all milk combinations
and ranged between 4.35 (BGRA43+WCM+1 % Nutrim®)
and 4.69 (BGRA43+RSM+1 % Nutrim®). After 7 days of
storage at 4 °C, the pH value was maintained above 4 in
all combinations when WGM was used. The most ex-
pressed changes of titratable acidity were detected be-
tween the first and seventh day of storage in all three
fermented milk products prepared from RSM (Table 3).
The value of viscosity was the lowest in the fer-
mented milk product obtained from WCM and it was
0.670 Pa·s after 0.5 min. The viscosity decreased during
shearing and after 3 min it was 0.468 Pa·s. Viscosity value
was the highest in the fermented milk product obtained
from WGM supplemented with inulin or Nutrim®. In
addition, viscosity values were decreased after 7 days of
storage at 4 °C except in the case when Nutrim® was
supplemented (Table 4).
Finally, the obtained products were evaluated senso-
rially by a group of five analysts one day after the pro-
duction. The best sensory scores were observed for fer-
mented milk products made from RSM, WCM and WGM
prepared with 1 % inulin (Table 5). These fermented
drinks were tasty, viscous, typically sour and refreshing,
without any sense of bitterness. The worst sensory eval-
uation was given for fermented milk products prepared
from RSM, WCM and WGM with 1 % Nutrim®, respec-
tively. The reason for such evaluation mainly originates
from the colour of the final products, because they be-
came greyish.
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Table 2. Peptides identified in the BLG hydrolysate produced
by Lactobacillus helveticus BGRA43
m(peptide)/Da Peptide identity∗ Sequence
559.94 BLG (2–6) IVTQT
572.18 BLG (71–75) IIAEK
915.33 BLG (84–91) IDALNENK
1436.43 BLG (127–138) EVDDEALEKFDK
1567.57 BLG (43–56) VEELKPTPEGDLEI
1680.67 BLG (43–57) VEELKPTPEGDLEIL
1730.68 BLG (42–56) YVEELKPTPEGDLEI
1942.64 BLG (41–57) VYVEELKPTPEGDLEIL
∗numbers refer to amino acid positions in the BLG protein se-
quence; sequences given in bold are part of allergenic epitopes
in the BLG
LIVTQTMKGL DIQKVAGTWY SLAMAASDIS LLDAQSAPLR
VYVEELKPTP EGDLEILLQK WENDECAQKK IIAEKTKIPA
VFKIDALNEN KVLVLDTDYK KYLLFCMENS AEPEQSLFCQ
CLVRTPEVDD EALEKFDKAL KALPMHIRLS FNPTQLEEQC HI
Fig. 2. Location of the main peptides (arrows) identified in the
primary sequence of BLG released after hydrolysis with Lacto-
bacillus helveticus BGRA43. Sequences given in bold are the al-































































Table 3. Monitoring of pH, titratable acidity (°SH) and cell survival (CFU/mL) of Lactobacillus helveticus BGRA43 in reconstituted skimmed milk (RSM), whole cow's milk (WCM) and whole
goat's milk (WGM) with or without 1 % inulin and 1 % Nutrim®. Each milk was inoculated with 3 % BGRA43 culture previously incubated in RSM for 16 h at 37 °C
Fermentation
time at 42 °C/h










0 6.7±0.1 10.0±0.0 (3.2±0.8)·106 6.6±0.1 13.6±1.0 (2.8±0.14)·106 6.6±0.1 11.6±1.5 (2.4±0.9)·106
2 5.3±0.2 19.2±2.4 5.3±0.2 18.8±1.7 5.4±0.8 18.4±1.9
3 5.0±0.2 22.0±1.7 5.0±0.2 21.6±1.7 5.1±0.1 20.0±0.0
3.5 4.8±0.2 24.8±1.8 4.7±0.2 24.4±2.4 4.9±0.2 21.2±2.2
4 4.6±0.2 27.6±2.1 4.5±0.2 27.6±1.9 4.7±0.2 26.8±2.8
Storage time at 4 °C
1 day 4.4±0.3 32.8±1.4 (4.1±0.9)·108 4.3±0.3 31.2±2.3 (2.5±0.2)·107 4.5±0.2 30.4±3.3 (4.8±0.7)·107
7 days 3.9±0.3 54.4±3.1 (2.3±0.5)·108 3.7±0.4 49.6±3.7 (1.2±0.3)·107 3.9±0.3 45.6±3.8 (1.1±0.3)·107
Fermentation
time at 42 °C/h










0 6.7±0.1 10.8±0.07 (2.9±0.3)·106 6.64±0.09 13.6±1.48 (3.6±0.8)·106 6.6±0.1 12.8±2.2 (4.3±0.6)·106
2 5.7±0.2 16.0±0.00 5.79±0.18 14.0±0.00 5.6±0.2 16.4±1.8
3 5.1±0.1 23.2±0.92 5.17±0.17 20.4±0.92 5.0±0.2 22.8±1.5
3.5 4. 8±0.2 28.8±1.11 4.81±0.17 26.8±2.64 4.7±0.2 30.4±2.1
4 4.6±0.2 39.2±2.05 4.45±0.19 31.6±1.77 4.4±0.2 36.0±0.0
Storage time at 4 °C
1 day 4.3±0.2 41.6±2.8 (1.9±1.0)·108 4.3±0.3 33.6±3.2 (2.4±0.5)·108 4.2±0.3 39.2±2.1 (3.7±0.5)·108
7 days 3.9±0.4 46.0±0.0 (7.0±0.8)·107 3.8±0.4 46.8±3.1 (7.0±0.4)·107 3.8±0.3 53.2±3.1 (1.2±0.0)·108
Fermentation
time at 42 °C/h










0 6.2±0.2 11.6±1.2 (5.6±0.7)·106 6.2±0.1 13.2±1.1 (1.9±0.7)·106 6.2±0.1 12.4±2.6 (3.1±0.6)·106
2 5.5±0.3 18.4±1.9 5.4±0.2 18.0±0.0 5.4±0.2 17.2±2.2
3 5.1±0.3 22.0±1.3 5.1±0.1 22.0±0.0 5.0±0.2 22.8±3.1
3.5 4.8±0.2 25.2±1.2 4.8±0.1 25.6±2.6 4.8±0.2 26.8±2.0
4 4.6±0.2 29.6±2.0 4.5±0.2 30.8±2.1 4.5±0.2 32.4±3.5
Storage time at 4 °C
1 day 4.4±0.2 35.2±3.1 (2.8±1.0)·108 4.4±0.2 36.8±4.1 (2.2±0.2)·108 4.3±0.3 39.2±2.9 (1.9±0.2)·108
7 days 4.3±0.3 41.6±2.6 (6.0±2.3)·107 4.2±0.3 46.0±0.0 (9.0±0.4)·107 4.07±0.3 50.8±3.7 (5.0±0.2)·107
Mean values±standard deviation for N=3
Discussion
In this study, the antimicrobial potential of Lactoba-
cillus helveticus BGRA43 against different human patho-
gens, its ability to survive in simulated gastrointestinal
conditions in the presence of milk and its ability to hy-
drolyze BLG was evaluated before using it as a mono-
culture for manufacturing of fermented products from dif-
ferent milk samples at laboratory scale. Our study showed
that BGRA43 exhibited broad antimicrobial spectrum.
Additionally, taking into account the fact that living cells
of BGRA43 are necessary for growth inhibition of patho-
gens, we can speculate that antimicrobial activity arises
from the synergistic action of organic acids synthesized
by BGRA43 cells. This assumption was supported by the
observation that narrow zone of inhibition was obtained
when acid-resistant S. flexneri clinical isolate was used as
indicator strain. However, additional experiments are
needed in order to make a final statement.
In vitro studies of bacteria have been used to evalu-
ate various characteristics of potential probiotics. Among
these, tolerances of the low pH in the stomach and bile
components in the proximal parts of the intestine seem
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Table 4. The influence of the investigated parameters on the viscosity changes of Lactobacillus helveticus BGRA43 in RSM, WCM and
WGM with or without 1 % inulin or 1 % Nutrim®
Product composition
t(storage at 4 °C)
day
t/min
0.5 1 1.5 2 2.5 3
h/(Pa·s)
BGRA43+RSM
1 0.879±0.009 0.843±0.009 0.812±0.009 0.785±0.009 0.772±0.008 0.740±0.008
7 0.823±0.010 0.804±0.009 0.775±0.008 0.768±0.008 0.755±0.008 0.711±0.008
BGRA43+RSM+1 % inulin
1 1.186±0.010 1.152±0.011 1.116±0.011 1.071±0.010 1.020±0.010 0.999±0.009
7 1.025±0.010 0.995±0.009 0.963±0.011 0.927±0.010 0.881±0.010 0.838±0.009
BGRA43+RSM+1 % Nutrim®
1 1.098±0.012 1.012±0.011 0.937±0.010 0.877±0.010 0.823±0.009 0.780±0.008
7 1.186±0.011 1.117±0.011 0.956±0.010 0.914±0.010 0.896±0.010 0.831 ±0.010
BGRA43+WCM
1 0.670±0.007 0.622±0.008 0.601±0.007 0.560±0.007 0.519±0.006 0.468±0.006
7 0.606±0.007 0.553±0.007 0.519±0.006 0.470±0.006 0.434±0.005 0.413±0.006
BGRA43+WCM+1 % inulin
1 0.810±0.010 0.799±0.008 0.761±0.009 0.724±0.008 0.700±0.008 0.660±0.007
7 0.776±0.009 0.736±0.009 0.708±0.009 0.661±0.008 0.626±0.007 0.598±0.006
BGRA43+WCM+1 % Nutrim®
1 0.763±0.008 0.725±0.008 0.689±0.008 0.632±0.008 0.579±0.007 0.529±0.007
7 0.789±0.008 0.758±0.008 0.727±0.008 0.681±0.007 0.646±0.008 0.606±0.007
BGRA43+WGM
1 1.165±0.013 1.033±0.012 0.976±0.011 0.961±0.011 0.948±0.011 0.924±0.010
7 1.101±0.012 0.987±0.010 0.942±0.010 0.905±0.010 0.877±0.009 0.820±0.010
BGRA43+WGM+1 % inulin
1 1.322±0.012 1.257±0.013 1.171±0.012 1.054±0.012 1.002±0.011 0.955±0.011
7 1.268±0.012 1.210±0.012 1.165±0.013 1.079±0.012 0.972±0.011 0.913±0.011
BGRA43+WGM+1 % Nutrim®
1 1.289±0.012 1.231±0.012 1.181±0.013 1.162±0.013 1.123±0.012 1.046±0.011
7 1.326±0.013 1.289±0.012 1.271±0.012 1.224±0.013 1.201±0.012 1.159±0.012
Mean values±standard deviation for N=3
Table 5. Sensory evaluations (grades 1- 5) of fermented milk products after 1 day of storage at 4 °C
Products composition
Sensory properties
Colour Taste Odour Consistency General appearance
BGRA43+RSM 3.5 3.0 2.5 3.5 4.0
BGRA43+RSM+1 % inulin 3.5 4.0 3.5 4.5 4.5
BGRA43+RSM+1 % Nutrim® 1.5 3.5 3.5 3.5 3.0
BGRA43+WCM 4.0 4.0 4.0 4.0 3.5
BGRA43+WCM+1 % inulin 4.5 4.0 4.5 4.5 4.0
BGRA43+WCM+1 % Nutrim® 2.0 3.5 3.5 3.0 3.0
BGRA43+WGM 5.0 4.5 4.5 4.5 5.0
BGRA43+WGM+1 % inulin 4.5 5.0 4.5 4.5 5.0
BGRA43+WGM+1 % Nutrim® 2.0 4.0 4.0 3.5 3.5
Data are mean values of evaluation scores obtained for each sample by five sensory analysts
to be very important (29). Strain BGRA43 is sensitive to
gastric conditions, i.e. low pH, judging by the decrease
of living cell numbers to 104 CFU/mL upon incubation
for 90 min in simulated gastric conditions. However,
BGRA43 showed remarkable survival in the simulated
gastric juice with milk. Moreover, it retained stability in
cell numbers during incubation in simulated intestinal
conditions. Kos et al. (5) obtained similar results for L.
acidophilus M92, showing that skimmed milk, whey pro-
tein concentrate and mucin function as buffering agents
and inhibitors of digestive proteases in vitro and so in-
crease their survival.
Published results show that three themophilic LAB
strains were able to degrade BLG during growth in CDM
and under starving conditions, giving different peptide
profiles (30). Results obtained for L. acidophilus CRL 636
showed that this strain preferentially cleaved BLG after
hydrophobic residues (31), as it was shown for BGRA43.
As shown in Fig. 2, BGRA43 was able to hydrolyze one
of the three major allergenic epitopes of BLG at Val41,
Tyr42, and Val43 positions. In general, the degradation of
BLG, a-lactalbumin and whey proteins was studied for
L. delbrueckii ssp. bulgaricus, Streptococcus thermophilus, L.
acidophilus (30), L. paracasei NCC2461 (32) and Bifidobac-
terium lactis NCC362 (33). To the best of our knowledge,
this is the first report on the ability of L. helveticus strain
to hydrolyse BLG.
Strain BGRA43 grew very well in the presence of ei-
ther inulin or Nutrim® even when they were the only
carbon source. Moreover, it also grew in cow's or goat's
milk with or without inulin or Nutrim®. The initial num-
ber of viable BGRA43 cells was 106 CFU/mL, which cor-
relates with the data reported by Dave and Shah (34)
and Deutsch et al. (35). When BGRA43 was used as a
single starter, the number of living cells in all prepared
final products corresponded to the required minimum
level of viable probiotic bacteria (36,37). In addition, our
results showed that the viable count of BGRA43 during
7 days of storage slightly decreased, which makes it
suitable for use as a potential probiotic starter strain.
According to the results obtained after viscosity mea-
surements, it was found that the viscosity values of all
products prepared with inulin or Nutrim® were higher
than the viscosity values of those prepared without pre-
biotics. Havrlentová et al. (38) reported similar data. Vis-
cosity values obtained for yoghurts prepared from com-
mercial UHT whole cow's milk were lower than the
viscosity values of yoghurts prepared from skimmed or
whole goat's milk. Our results are in agreement with
those obtained previously in study of Labropoulos et al.
(28), who reported that high temperature treatments of
milk cause a decrease in the viscosity of yoghurt. Addi-
tionally, it was noticed that viscosity of all tested fer-
mented milk products made with Nutrim® became high-
er after 7 days of storage at 4 °C, which correlates with
the results obtained by Inglett et al. (39). Sensory charac-
teristics mainly depend on milk type and its composi-
tion, as well as on starter culture used for fermentation.
In our study, all fermented milk products prepared with
inulin showed very good to excellent sensory features.
L. helveticus is used as starter culture in a variety of fer-
mented dairy products as flavour enhancer and it is ca-
pable of reducing bitterness (40). This is probably the
reason why the obtained fermented milk products con-
taining inulin showed no bitter taste. The lowest scores
given to fermented milk products supplemented with
Nutrim® are related to the colour change of final prod-
ucts. According to the results presented by Park et al.
(41), dark colour of Nutrim® is associated with polyphe-
nol oxidase activity.
Conclusions
It was determined that Lactobacillus helveticus BGRA43
could be considered as a potential probiotic candidate
with suitable technological properties. The strain is able
to reduce the allergenicity of BLG, which can contribute
to obtaining a product not only with probiotic character-
istics but also with better digestibility, especially in peo-
ple who are allergic to cow's milk. Moreover, it may be
used as a single starter for the preparation of fermented
milk products from bovine or caprine milk.
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